MTNB Matinas BioPharma: Rasio rega marang prakiraan pendapatan
Matinas BioPharma develops oral formulations of complex drugs through alliances with industry leaders. The company's P/S expectations confirm this trajectory, where 41.80 records a new level. The unique LNC platform protects the business with patents, paving the way for licensing. While clinical trials for anti-infective agents are currently expanding, the lack of revenue temporarily increases laboratory costs.
Ringkesan rincian data analitis matinasbiopharma.com (MTNB)
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Matinas BioPharma|MTNB - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Matinas BioPharma Holdings|MTNB - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Matinas BioPharma|MTNB - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Matinas BioPharma|Rasio cepet matinasbiopharma.com
- rincian asil keuangan lan kelipatan valuasi:
MTNB - Asil keuangan resik|Bathi sing dikarepake Matinas BioPharma|MTNB - Pangali rega marang bathi|Pangali Forward P/E Matinas BioPharma Holdings|MTNB - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Matinas BioPharma|MTNB - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Matinas BioPharma|MTNB - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan matinasbiopharma.com|MTNB - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Matinas BioPharma
- indikator volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:Matinas BioPharma Holdings Inc. MTNB
The forward P/S ratio compares current market capitalization with projected annual revenue, allowing investors to perform a real-time assessment of the value of future sales flows. For Matinas BioPharma (MTNB), which lacks commercial products and is burdened by high R&D costs, the current forward P/S level reflects speculative market expectations regarding the success of clinical trials rather than actual operational efficiency.
Pesaing Matinas BioPharma
Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Rasio rega marang prakiraan pendapatan Amicus Therapeutics FOLD|ETNB - Multiplikator forward rega marang pendapatan|Agios Pharmaceuticals, Inc. - Multiplikator Forward P/S|GPCR - Multiplikator Forward P/S|MDXG (MiMedx Group) - Multiplikator forward rega marang pendapatan|RZLT: Rasio rega marang pendapatan sing dikarepake|LXRX (Lexicon Pharmaceuticals) - Multiplikator Forward P/S|mbxbio.com (MBX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Altimmune (ALT)|Aardvark Therapeutics Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S SGMT (Sagimet)|Multiplikator Forward P/S BioAge Labs, Inc BIOA|BMEA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Quince Therapeutics QNCX|GUTS (Fractyl Health) - Multiplikator forward rega marang pendapatan|vTv Therapeutics - Rega forward marang dodolan|ATPC (Agape ATP Corp) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan PLUR|Multiplikator Forward P/S SYBX|Rasio kapitalisasi marang dodolan sing dikarepake lipocine.com|Rasio rega marang prakiraan pendapatan Spruce Biosciences, Inc. SPRB|Galecto Inc (GLTO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CTCX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan LUMO|ONVO: Multiplikator Forward P/S|radiuspharm.com - Rega forward marang dodolan
